Revathi Ananthakrishnan

5.5k total citations · 2 hit papers
43 papers, 4.0k citations indexed

About

Revathi Ananthakrishnan is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Revathi Ananthakrishnan has authored 43 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Revathi Ananthakrishnan's work include CAR-T cell therapy research (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cellular Mechanics and Interactions (8 papers). Revathi Ananthakrishnan is often cited by papers focused on CAR-T cell therapy research (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cellular Mechanics and Interactions (8 papers). Revathi Ananthakrishnan collaborates with scholars based in United States, Japan and France. Revathi Ananthakrishnan's co-authors include Josef A. Käs, Jochen Guck, C. Casey Cunningham, Allen J. Ehrlicher, Tess J. Moon, Falk Wottawah, Bryan Lincoln, Stefan Schinkinger, Daniel A. Mitchell and Dominik Lenz and has published in prestigious journals such as Physical Review Letters, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Revathi Ananthakrishnan

41 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Optical Deformability as an Inherent Cell Marker for Testing Malignant Transformation and Metastatic Competence

2005 1.1k citations Jochen Guck, Stefan Schinkinger et al. Biophysical Journal profile →
The Optical Stretcher: A Novel Laser Tool to Micromanipulate Cells

2001 715 citations Jochen Guck, Revathi Ananthakrishnan et al. Biophysical Journal profile →

Peers

Countries citing papers authored by Revathi Ananthakrishnan

Since Specialization

Citations

This map shows the geographic impact of Revathi Ananthakrishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Revathi Ananthakrishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Revathi Ananthakrishnan more than expected).

Fields of papers citing papers by Revathi Ananthakrishnan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Revathi Ananthakrishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Revathi Ananthakrishnan. The network helps show where Revathi Ananthakrishnan may publish in the future.

Co-authorship network of co-authors of Revathi Ananthakrishnan

This figure shows the co-authorship network connecting the top 25 collaborators of Revathi Ananthakrishnan. A scholar is included among the top collaborators of Revathi Ananthakrishnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Revathi Ananthakrishnan. Revathi Ananthakrishnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials 2025 ·Therapeutic Innovation & Regulatory Science ·Philip He, Haijun Ma, (unknown), Revathi Ananthakrishnan, Gu Mi, Thomas Gwise, Laura L. Fernandes, (unknown), David Leung, (unknown), Sohail S. Chaudhry	0
2	CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, (unknown), (unknown), (unknown), Serena Perna, Sherilyn A. Tuazon, San‐San Ou, Sahar Ansari, (unknown), (unknown), Revathi Ananthakrishnan, (unknown), Leanne Peiser, Tanya Siddiqi	3
3	Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, (unknown), Pradipta Ray, (unknown), Serena Perna, Sherilyn A. Tuazon, (unknown), Sahar Ansari, (unknown), (unknown), Revathi Ananthakrishnan, (unknown), Leanne Peiser, Tanya Siddiqi	1
4	Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma 2023 ·International Journal of Hematology ·(unknown), Tadao Ishida, Kiyoshi Ando, Rikio Suzuki, Junji Tanaka, Shotaro Hagiwara, Revathi Ananthakrishnan, (unknown), (unknown), Yoshinobu Kanda, Kenshi Suzuki	15
5	Critical review of oncology clinical trial design under non-proportional hazards 2021 ·Critical Reviews in Oncology/Hematology ·Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, Rong Liu, Daniel Li, Michael P. LaValley	17
6	Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials 2018 ·Contemporary Clinical Trials Communications ·Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael P. LaValley	4
7	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma 2016 ·Clinical Cancer Research ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, (unknown), M. Luisa Paccagnella, Joseph Boni, Erik Vandendries, David MacDonald	28
8	Systematic comparison of the statistical operating characteristics of various Phase I oncology designs 2016 ·Contemporary Clinical Trials Communications ·Revathi Ananthakrishnan, Stephanie Green, Mark Chang, Gheorghe Doros, Joseph M. Massaro, Michael P. LaValley	15
9	A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy 2016 ·British Journal of Haematology ·André Goy, Andres Forero, Nina D. Wagner‐Johnston, W. Christopher Ehmann, Michaela L. Tsai, Kiyohiko Hatake, Revathi Ananthakrishnan, Angela Volkert, Erik Vandendries, Michinori Ogura	40
10	Design of oncology clinical trials: A review 2013 ·Critical Reviews in Oncology/Hematology ·Revathi Ananthakrishnan, Sandeep Menon	14
11	Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL) 2013 ·Blood ·Randeep Sangha, Andrew Davies, Nam H. Dang, Michinori Ogura, David MacDonald, Angela Volkert, Revathi Ananthakrishnan, Kenneth T. Luu, Joseph Boni, Erik Vandendries, (unknown)	2
12	Integration of cell biology, pharmacological modeling and statistical analysis 2011 ·Critical Reviews in Oncology/Hematology ·Revathi Ananthakrishnan, Sandeep Menon	1
13	Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma 2011 ·European Journal of Cancer ·Birgit Geoerger, Mark W. Kieran, Stephan A. Grupp, Danuta Perek, Jill S. Clancy, Mizue Krygowski, Revathi Ananthakrishnan, Joseph Boni, Anna Berkenblit, Sheri L. Spunt	103
14	The Forces Behind Cell Movement 2007 ·International Journal of Biological Sciences ·Revathi Ananthakrishnan, Allen J. Ehrlicher	323
15	Quantifying the contribution of actin networks to the elastic strength of fibroblasts 2006 ·Journal of Theoretical Biology ·Revathi Ananthakrishnan, Jochen Guck, Falk Wottawah, Stefan Schinkinger, Bryan Lincoln, (unknown), Tess J. Moon, Josef A. Käs	76
16	Modelling the structural response of an eukaryotic cell in the optical stretcher 2005 ·Current Science ·Revathi Ananthakrishnan, Jochen Guck, Falk Wottawah, Stefan Schinkinger, Bryan Lincoln, (unknown), Josef A. Käs	14
17	Optical Rheology of Biological Cells 2005 ·Physical Review Letters ·Falk Wottawah, Stefan Schinkinger, Bryan Lincoln, Revathi Ananthakrishnan, (unknown), Jochen Guck, Josef A. Käs	179
18	Weak Force Stalls Protrusion at the Leading Edge of the Lamellipodium 2005 ·Biophysical Journal ·(unknown), Revathi Ananthakrishnan, Alex Mogilner, Jean-Jacques Meister, Alexander B. Verkhovsky	48
19	The Optical Stretcher: A Novel Laser Tool to Micromanipulate Cells breakdown → 2001 ·Biophysical Journal ·Jochen Guck, Revathi Ananthakrishnan, (unknown), Tess J. Moon, C. Casey Cunningham, Josef A. Käs	715
20	Optical Deformability of Soft Biological Dielectrics 2000 ·Physical Review Letters ·Jochen Guck, Revathi Ananthakrishnan, T. Moon, C. Casey Cunningham, Josef A. Käs	225

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact